Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selection.

Muscat AM, Wong NC, Drummond KJ, Algar EM, Khasraw M, Verhaak R, Field K, Rosenthal MA, Ashley DM.

Oncotarget. 2017 Dec 15;9(8):7844-7858. doi: 10.18632/oncotarget.23541. eCollection 2018 Jan 30.

2.

Glioma Through the Looking GLASS: Molecular Evolution of Diffuse Gliomas and the Glioma Longitudinal AnalySiS Consortium.

Aldape K, Amin SB, Ashley DM, Barnholtz-Sloan JS, Bates AJ, Beroukhim R, Bock C, Brat DJ, Claus EB, Costello JF, de Groot JF, Finocchiaro G, French PJ, Gan HK, Griffith B, Herold-Mende CC, Horbinski C, Iavarone A, Kalkanis SN, Karabatsou K, Kim H, Kouwenhoven MCM, McDonald KL, Miletic H, Nam DH, Ng HK, Niclou SP, Noushmehr H, Ormond R, Poisson LM, Reifenberger G, Roncaroli F, Sa JK, Sillevis Smitt PAE, Smits M, Souza CF, Tabatabai G, Van Meir EG, Verhaak RGW, Watts C, Wesseling P, Woehrer A, Yung WKA, Jungk C, Hau AC, van Dyck E, Westerman BA, Yin J, Abiola O, Zeps N, Grimmond S, Buckland M, Khasraw M, Sulman EP, Muscat AM, Stead L; GLASS Consortium.

Neuro Oncol. 2018 Feb 8. doi: 10.1093/neuonc/noy020. [Epub ahead of print]

PMID:
29432615
3.

Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study.

Wann A, Tully PA, Barnes EH, Lwin Z, Jeffree R, Drummond KJ, Gan H, Khasraw M.

J Neurooncol. 2018 Apr;137(2):409-415. doi: 10.1007/s11060-017-2731-2. Epub 2018 Jan 2.

PMID:
29294233
4.

The epidemiology of hip fractures across western Victoria, Australia.

Holloway KL, Sajjad MA, Mohebbi M, Kotowicz MA, Livingston PM, Khasraw M, Hakkennes S, Dunning TL, Brumby S, Page RS, Pedler D, Sutherland A, Venkatesh S, Brennan-Olsen SL, Williams LJ, Pasco JA.

Bone. 2018 Mar;108:1-9. doi: 10.1016/j.bone.2017.12.007. Epub 2017 Dec 8.

PMID:
29229437
5.

Geographic region, socioeconomic position and the utilisation of primary total joint replacement for hip or knee osteoarthritis across western Victoria: a cross-sectional multilevel study of the Australian Orthopaedic Association National Joint Replacement Registry.

Brennan-Olsen S, Vogrin S, Holloway KL, Page RS, Sajjad MA, Kotowicz MA, Livingston PM, Khasraw M, Hakkennes S, Dunning TL, Brumby S, Pedler D, Sutherland A, Venkatesh S, Williams LJ, Duque G, Pasco JA.

Arch Osteoporos. 2017 Nov 6;12(1):97. doi: 10.1007/s11657-017-0396-2.

PMID:
29110097
6.

Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey.

Leyden J, Pavlakis N, Chan D, Michael M, Clarke S, Khasraw M, Price T.

Asia Pac J Clin Oncol. 2017 Nov 6. doi: 10.1111/ajco.12785. [Epub ahead of print]

PMID:
29105989
7.

Evaluating the role of Magnetic Resonance Imaging post Neoadjuvant Therapy for Breast Cancer in the NEONAB trial.

Murphy C, Mukaro V, Tobler R, Asher R, Gibbs E, West L, Giuffre B, Baron-Hay S, Khasraw M.

Intern Med J. 2017 Sep 4. doi: 10.1111/imj.13617. [Epub ahead of print]

PMID:
28869790
8.

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.

Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD; GBM AGILE Network.

Clin Cancer Res. 2018 Feb 15;24(4):737-743. doi: 10.1158/1078-0432.CCR-17-0764. Epub 2017 Aug 16. Review.

PMID:
28814435
9.

Combination of palbociclib and radiotherapy for glioblastoma.

Whittaker S, Madani D, Joshi S, Chung SA, Johns T, Day B, Khasraw M, McDonald KL.

Cell Death Discov. 2017 Jul 3;3:17033. doi: 10.1038/cddiscovery.2017.33. eCollection 2017.

10.

Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.

Harris G, Jayamanne D, Wheeler H, Gzell C, Kastelan M, Schembri G, Brazier D, Cook R, Parkinson J, Khasraw M, Louw S, Back M.

Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):802-810. doi: 10.1016/j.ijrobp.2017.02.028. Epub 2017 Feb 21.

PMID:
28602411
11.

Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.

Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, Barnes T, Diakos C, Khasraw M, Samra J, Eslick E, Roach PJ, Engel A, Clarke SJ, Bailey DL.

Theranostics. 2017 Mar 1;7(5):1149-1158. doi: 10.7150/thno.18068. eCollection 2017.

12.

Immune Checkpoint Inhibitors for Brain Metastases.

Tan AC, Heimberger AB, Menzies AM, Pavlakis N, Khasraw M.

Curr Oncol Rep. 2017 Jun;19(6):38. doi: 10.1007/s11912-017-0596-3. Review.

PMID:
28417311
13.

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma.

Jue TR, Nozue K, Lester AJ, Joshi S, Schroder LB, Whittaker SP, Nixdorf S, Rapkins RW, Khasraw M, McDonald KL.

J Transl Med. 2017 Mar 17;15(1):61. doi: 10.1186/s12967-017-1164-1.

14.

Immune Checkpoint Inhibitors in Gliomas.

Tan AC, Heimberger AB, Khasraw M.

Curr Oncol Rep. 2017 Apr;19(4):23. doi: 10.1007/s11912-017-0586-5. Review.

PMID:
28303490
15.

The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.

Li BT, Barnes TA, Chan DL, Naidoo J, Lee A, Khasraw M, Marx GM, Kris MG, Clarke SJ, Drilon A, Rudin CM, Pavlakis N.

Lung Cancer. 2016 Dec;102:21-27. doi: 10.1016/j.lungcan.2016.10.004. Epub 2016 Oct 17.

16.

Reply to Dr Altundag from the authors of 'Management of breast cancer brain metastases; a practical review'.

Phillips C, Jeffree R, Khasraw M.

Breast. 2017 Aug;34:133. doi: 10.1016/j.breast.2016.11.026. Epub 2016 Dec 9. No abstract available.

PMID:
27955975
17.

Management of breast cancer brain metastases: A practical review.

Phillips C, Jeffree R, Khasraw M.

Breast. 2017 Feb;31:90-98. doi: 10.1016/j.breast.2016.10.006. Epub 2016 Nov 6. Review.

PMID:
27829201
18.

Ageing, Chronic Disease and Injury: A Study in Western Victoria (Australia).

Sajjad MA, Holloway KL, Kotowicz MA, Livingston PM, Khasraw M, Hakkennes S, Dunning TL, Brumby S, Page RS, Pedler D, Sutherland A, Venkatesh S, Brennan-Olsen SL, Williams LJ, Pasco JA.

J Public Health Res. 2016 Aug 19;5(2):678. eCollection 2016 Aug 19.

19.

Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?

Lester A, Rapkins R, Nixdorf S, Khasraw M, McDonald K.

Clin Transl Oncol. 2017 Mar;19(3):273-278. doi: 10.1007/s12094-016-1547-4. Epub 2016 Sep 21. Review.

PMID:
27655368
20.

Prioritization schema for immunotherapy clinical trials in glioblastoma.

Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB.

Oncoimmunology. 2016 Feb 18;5(6):e1145332. doi: 10.1080/2162402X.2016.1145332. eCollection 2016 Jun. Review.

21.

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.

Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB.

Neuro Oncol. 2016 Oct;18(10):1357-66. doi: 10.1093/neuonc/now132. Epub 2016 Jul 1.

22.

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.

Segelov E, Waring P, Desai J, Wilson K, Gebski V, Thavaneswaran S, Elez E, Underhill C, Pavlakis N, Chantrill L, Nott L, Jefford M, Khasraw M, Day F, Wasan H, Ciardiello F, Karapetis C, Joubert W, van Hazel G, Haydon A, Price T, Tejpar S, Tebbutt N, Shapiro J.

BMC Cancer. 2016 May 31;16:339. doi: 10.1186/s12885-016-2389-8.

23.

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.

Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, Gebski VJ, Elez E, Nott LM, Karapetis CS, Lunke S, Chantrill LA, Pavlakis N, Khasraw M, Underhill C, Ciardiello F, Jefford M, Wasan H, Haydon A, Price TJ, van Hazel G, Wilson K, Simes J, Shapiro JD.

J Clin Oncol. 2016 Jul 1;34(19):2258-64. doi: 10.1200/JCO.2015.65.6843. Epub 2016 Apr 25.

PMID:
27114605
24.

A Discrete Choice Experiment to Examine the Preferences of Patients With Cancer and Their Willingness to Pay for Different Types of Health Care Appointments.

Wong SF, Norman R, Dunning TL, Ashley DM, Khasraw M, Hayes TM, Collins I, Lorgelly PK.

J Natl Compr Canc Netw. 2016 Mar;14(3):311-9. Epub 2016 Mar 8.

PMID:
26957617
25.

Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.

Khasraw M, Lee A, McCowatt S, Kerestes Z, Buyse ME, Back M, Kichenadasse G, Ackland S, Wheeler H.

J Neurooncol. 2016 May;128(1):163-171. doi: 10.1007/s11060-016-2094-0. Epub 2016 Mar 2.

PMID:
26935578
26.

Use of targeted therapy in cancer patients in the end-of-life period: results from an Australian centre.

Wann A, Ashley D, Khasraw M.

Support Care Cancer. 2016 Jul;24(7):3023-8. doi: 10.1007/s00520-016-3124-3. Epub 2016 Feb 18.

PMID:
26887377
27.

Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy.

Khasraw M, Ananda S, Michael M.

Expert Rev Anticancer Ther. 2016;16(4):391-401. doi: 10.1586/14737140.2016.1146135. Epub 2016 Feb 17. Review.

PMID:
26808925
28.

EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model.

Wang T, Gantier MP, Xiang D, Bean AG, Bruce M, Zhou SF, Khasraw M, Ward A, Wang L, Wei MQ, AlShamaileh H, Chen L, She X, Lin J, Kong L, Shigdar S, Duan W.

Theranostics. 2015 Oct 20;5(12):1456-72. doi: 10.7150/thno.11692. eCollection 2015.

29.

Evolving management of low grade glioma: No consensus amongst treating clinicians.

Field KM, Rosenthal MA, Khasraw M, Sawkins K, Nowak AK.

J Clin Neurosci. 2016 Jan;23:81-7. doi: 10.1016/j.jocn.2015.05.038. Epub 2015 Oct 23.

PMID:
26601811
30.

Retrospective analysis of cancer survival across South-Western Victoria in Australia.

Wong SF, Matheson L, Morrissy K, Pitson G, Ashley DM, Khasraw M, Lorgelly PK, Henry MJ.

Aust J Rural Health. 2016 Apr;24(2):79-84. doi: 10.1111/ajr.12203. Epub 2015 Jun 29.

PMID:
26122852
31.

CDK4/6 inhibitors in breast cancer.

Dukelow T, Kishan D, Khasraw M, Murphy CG.

Anticancer Drugs. 2015 Sep;26(8):797-806. doi: 10.1097/CAD.0000000000000249. Review.

PMID:
26053278
32.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review.

PMID:
25242542
33.

Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis.

Ameratunga M, Pavlakis N, Gebski V, Broad A, Khasraw M.

Asia Pac J Clin Oncol. 2014 Sep;10(3):273-8. doi: 10.1111/ajco.12231.

PMID:
25135201
34.

Patterns of care in adult medulloblastoma: results of an international online survey.

Cosman R, Brown CS, DeBraganca KC, Khasraw M.

J Neurooncol. 2014 Oct;120(1):125-9. doi: 10.1007/s11060-014-1525-z. Epub 2014 Jul 16.

PMID:
25026996
35.

Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.

Khasraw M, Ameratunga M, Grommes C.

Expert Opin Biol Ther. 2014 May;14(5):729-40. doi: 10.1517/14712598.2014.898060. Epub 2014 Mar 22. Review.

PMID:
24655021
36.

Machine-learning prediction of cancer survival: a retrospective study using electronic administrative records and a cancer registry.

Gupta S, Tran T, Luo W, Phung D, Kennedy RL, Broad A, Campbell D, Kipp D, Singh M, Khasraw M, Matheson L, Ashley DM, Venkatesh S.

BMJ Open. 2014 Mar 17;4(3):e004007. doi: 10.1136/bmjopen-2013-004007.

37.

Brain metastases in breast cancer.

Sim HW, Morris PG, Patil S, Khasraw M.

Expert Rev Anticancer Ther. 2014 Feb;14(2):173-83. doi: 10.1586/14737140.2014.863468. Epub 2013 Dec 2. Review.

PMID:
24308683
38.

Emerging pharmacotherapy for cancer patients with cognitive dysfunction.

Davis J, Ahlberg FM, Berk M, Ashley DM, Khasraw M.

BMC Neurol. 2013 Oct 24;13:153. doi: 10.1186/1471-2377-13-153. Review.

39.

Small bowel video capsule endoscopy: an overview.

Mustafa BF, Samaan M, Langmead L, Khasraw M.

Expert Rev Gastroenterol Hepatol. 2013 May;7(4):323-9. doi: 10.1586/egh.13.20. Review.

PMID:
23639090
40.

Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy.

Khasraw M, Yap SY, Ananda S.

Expert Rev Anticancer Ther. 2013 Apr;13(4):451-9. doi: 10.1586/era.13.22. Review.

PMID:
23560839
41.

Alternative targeted therapy for early Her2 positive breast cancer.

Harvey SL, Khasraw M.

Gland Surg. 2013 Feb;2(1):42-5. doi: 10.3978/j.issn.2227-684X.2013.02.06. No abstract available.

42.

Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.

Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I.

Neuro Oncol. 2013 Feb;15(2):242-50. doi: 10.1093/neuonc/nos295. Epub 2012 Dec 14.

43.

Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.

Domchek SM, Jhaveri K, Patil S, Stopfer JE, Hudis C, Powers J, Stadler Z, Goldstein L, Kauff N, Khasraw M, Offit K, Nathanson KL, Robson M.

Cancer. 2013 Apr 1;119(7):1344-8. doi: 10.1002/cncr.27842. Epub 2012 Nov 16.

44.

Using lithium as a neuroprotective agent in patients with cancer.

Khasraw M, Ashley D, Wheeler G, Berk M.

BMC Med. 2012 Nov 2;10:131. doi: 10.1186/1741-7015-10-131. Review.

45.

Primary systemic therapy in HER2-amplified breast cancer: a clinical review.

Khasraw M, Bell R.

Expert Rev Anticancer Ther. 2012 Aug;12(8):1005-13. doi: 10.1586/era.12.62. Review.

PMID:
23030220
46.

Colorectal cancer: is the incidence rising in young Iraqi patients?

Sheet SY, Sheikha AK, Saeed AM, Ameen HA, Mohammed SS, Khasraw M.

Asia Pac J Clin Oncol. 2012 Dec;8(4):380-1. doi: 10.1111/j.1743-7563.2012.01524.x. Epub 2012 May 2. Review. No abstract available.

PMID:
22897829
47.

Bevacizumab for the treatment of high-grade glioma.

Khasraw M, Simeonovic M, Grommes C.

Expert Opin Biol Ther. 2012 Aug;12(8):1101-11. doi: 10.1517/14712598.2012.694422. Epub 2012 Jun 5. Review.

PMID:
22663137
48.

Epirubicin: is it like doxorubicin in breast cancer? A clinical review.

Khasraw M, Bell R, Dang C.

Breast. 2012 Apr;21(2):142-9. doi: 10.1016/j.breast.2011.12.012. Epub 2012 Jan 17. Review.

PMID:
22260846
49.

Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience.

Khasraw M, Holodny A, Goldlust SA, DeAngelis LM.

Ann Oncol. 2012 Feb;23(2):458-63. doi: 10.1093/annonc/mdr148. Epub 2011 May 4.

PMID:
21543627
50.

Neurological complications of systemic cancer.

Khasraw M, Posner JB.

Lancet Neurol. 2010 Dec;9(12):1214-1227. doi: 10.1016/S1474-4422(10)70220-9. Review.

PMID:
21087743

Supplemental Content

Loading ...
Support Center